Strategic product launch Arch has recently launched AC5 Advanced Wound System and is actively marketing it at major wound care events, indicating growing sales efforts and opportunities to engage distributors, hospitals, and wound care centers seeking innovative hemostatic and wound management solutions.

Regulatory approvals Regulatory authorization to market AC5 products in the United States and Europe creates near-term sales potential across large, multi-payer markets, enabling BD outreach to hospital networks, surgical centers, and regional procurement teams.

Clinical adoption Ongoing and completed studies, including multi-site trials and demonstrations of benefit in challenging wounds, provide evidence to support clinician-facing value propositions and payer justifications for AC5 in wound care pathways.

Partnerships and distribution Existing distribution collaboration with Centurion Therapeutics and ongoing channel development signal accessible routes to large tissue banks and surgical supply networks, presenting faster entry points for AC5 products.

Funding and growth Bridge financing and strategic fundraising activity, combined with a clear expansion plan, indicate readiness for scale, suggesting sales strategy should target investors’ portfolios and partner channels aligned with growth in biosurgical devices.